Additionally, even though LKB1 loss, per se, did not correlate with lymph node metastasis, when it co-occurred with KRAS mutations (KL) or as a component of KPL status, 100% of the KL and KPL (16/16 and 1/1) tumors showed lymph node metastasis versus only half (50% (3/6)) of the mono-mutational L cohort (LKB1 loss only, KRAS: wild type, p53: wild type, p16: not downregulated) with lymph node metastasis (p = 0.032). Here, KRAS is linked to metastatic malignant neoplasm in the lymph nodes.